DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma |
|
|
| Recruiting | 2/3 | 420 | Europe, Canada, US, RoW | IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome | IDEAYA Biosciences | Metastatic Uveal Melanoma | 01/27 | 01/28 | | |
NCT06660407: Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 20 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Immunotherapy, Immunological, Immunological Therapy, Immunologically Directed Therapy, Palliative Radiation Therapy, Palliative Radiotherapy, Spatially-fractionated Radiation Therapy, GRID Therapy, SFRT | Mayo Clinic | Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC V8 | 01/27 | 01/27 | | |
| Terminated | 1 | 50 | US, RoW | MT-5111 (experimental study drug) | Molecular Templates, Inc. | HER2-positive Solid Cancers | 02/23 | 04/23 | | |
